BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

Hesperos’ Human-on-a-Chip techIn an Advanced Therapeutics paper, a University of Central Florida team led by Hesperos Inc. co-founder and chief scientist James Hickman tested the efficacy of...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jun 25, 2019
Preclinical News

Alnylam preclinical data latest sign companies still plugging away at oral oligos

...disease. In 2014, Celgene payed Nogra Pharma Ltd. $710 million up front for the GI-targeted anti-SMAD7...
BioCentury | Feb 20, 2019
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Amplifications in GATA4 or alterations in SMAD4 could help predict survival in esophageal adenocarcinoma. In patients, whole-genome sequencing and RNA sequencing analysis of 551 esophageal adenocarcinoma samples identified associations between poor survival...
BioCentury | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
BioCentury | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
BioCentury | Aug 10, 2018
Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
BioCentury | Feb 28, 2018
Financial News

Celgene's slide continues after refusal to file letter

...Phase III failure of mongersen (GED-0301), an antisense oligonucleotide targeting SMAD family member 7 (MADH7; SMAD7...
BioCentury | Nov 3, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...following an interim futility analysis. Mongersen, an antisense oligonucleotide targeting SMAD family member 7 (SMAD7; MADH7...
BioCentury | Oct 30, 2017
Clinical News

Celgene reports detailed Phase III data for MS candidate ozanimod

...interim futility analysis. Mongersen, an antisense oligonucleotide targeting SMAD family member 7 ( SMAD7 ; MADH7...
Items per page:
1 - 10 of 81